TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29534063

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) tool for anticoagulant therapy adherence
Number of subjects: 8292

Group type: COMPARATOR
Intervention: Control group (no CDS intervention)
Number of subjects: 8292

Group type: EXPERIMENTAL
Intervention: CDS group
Number of subjects: 8292

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8292
Study: 27765693

Group type: EXPERIMENTAL
Intervention: Dance for Parkinson's classes (N = 8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: PD support groups (N = 7)
Number of subjects: 15
Study: 24180264

Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices classes (n = 24) with home practice
Number of subjects: 47

Group type: COMPARATOR
Intervention: Reading control condition (n = 23)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups (Mindfulness and Control)
Number of subjects: 47
Study: 23070486

Group type: EXPERIMENTAL
Intervention: Rilonacept (2.2 mg/kg, maximum 160 mg) by weekly subcutaneous injection for two 3-month courses
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo for two 3-month courses
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 21073556

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proton Pump Inhibitors (PPIs) like omeprazole and esomeprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: NSAIDs that do not interact with aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 0
Study: 19018918

Group type: EXPERIMENTAL
Intervention: Academic detailing intervention
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 284
Study: 16100136

Group type: EXPERIMENTAL
Intervention: Gentamicin 240 mg IV once daily
Number of subjects: 24
Study: 11852166

Group type: EXPERIMENTAL
Intervention: U.S. regulatory requirements for human subject protection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substudies within ESPRIT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attitudes and experiences across countries regarding ethical issues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insight into U.S. regulatory processes
Number of subjects: 0
Study: 9852390

Group type: EXPERIMENTAL
Intervention: GnRHa + add-back therapy (20 microg of ethinyl estradiol with 0.15 mg desogestrel)
Number of subjects: 27

Group type: COMPARATOR
Intervention: GnRHa + placebo
Number of subjects: 27
Study: 7864265

Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 60 mg/day)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 2200195

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Combined treatment (radio- and chemotherapy with prospidine)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Surgery (vestibular cord cancer stage II)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Combined treatment (vestibular cord cancer stage II)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Radiotherapy (vestibular cord cancer stage II)
Number of subjects: 269
Study: 6986976

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hypophysectomy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tamoxifen (post-hypophysectomy phase)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sequence of hypophysectomy followed by tamoxifen
Number of subjects: 26
Study: 31733423

Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD) 20 μg, s.c., once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Percutaneous vertebroplasty (PVP) plus alendronate (70 mg, p.o., once weekly)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cost of TPTD treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cost of PVP treatment
Number of subjects: 60
Study: 31059579

Group type: EXPERIMENTAL
Intervention: Static cyclotorsion compensation (SCC) group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 28088167

Group type: EXPERIMENTAL
Intervention: ARMS-I (Halo™), sprayed intra-orally 3 times daily for 75 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ARMS-I (Halo™)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25449059

Group type: EXPERIMENTAL
Intervention: Inhaled tiotropium 18 μg once daily for 1 month (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment, n = 10)
Number of subjects: 20
Study: 23706946

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Pro re nata dosing
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Genotype on 4 SNPs (rs1061170, rs10490924, rs11200638, rs2230199)
Number of subjects: 1185
Study: 21381953

Group type: EXPERIMENTAL
Intervention: Totally tubeless PCNL (group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard PCNL (group B)
Number of subjects: 70
Study: 19080748

Group type: EXPERIMENTAL
Intervention: Minimally invasive neurosurgery or intravenous hemostatics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimized medical care according to ICH treatment guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stem cell therapy
Number of subjects: 0
Study: 17173226

Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg every 6 hours)
Number of subjects: 14
Study: 14723798

Group type: EXPERIMENTAL
Intervention: CPB with hypothermia (mean 28 degrees C)
Number of subjects: 78

Group type: COMPARATOR
Intervention: CABG with beating heart (no CPB) or peripheral vascular surgery with normothermia
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CPB with hypothermia and local ice‐slush application
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: CPB with hypothermia
Number of subjects: 78
Study: 11723779

Group type: EXPERIMENTAL
Intervention: ADCON-T/N
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study: 9602314

Group type: EXPERIMENTAL
Intervention: Radiation therapy (24 Gy in four fractions of 6 Gy)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 74
Study: 8044597

Group type: EXPERIMENTAL
Intervention: Compression stockings during surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: No compression stockings during surgery
Number of subjects: 40
Study: 2897978

Group type: EXPERIMENTAL
Intervention: Suriclone 0.8 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Suriclone 0.2 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Suriclone 0.4 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Suriclone 0.6 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 54
Study: 31208412

Group type: EXPERIMENTAL
Intervention: Laquinimod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29074128

Group type: EXPERIMENTAL
Intervention: Video double-lumen tube (VDLT)
Number of subjects: 80
Study: 26826647

Group type: EXPERIMENTAL
Intervention: High cognitive load participants (n=425)
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Low cognitive load participants (n=593)
Number of subjects: 1018
Study: 24783193

Group type: EXPERIMENTAL
Intervention: 12-lipoxygenase (12-LOX) concentration in platelet-rich plasma
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Standardization to thromboglobulin (TGB) and platelet count
Number of subjects: 149
Study: 22576074

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg intravenous ketamine
Number of subjects: 80

Group type: COMPARATOR
Intervention: 100 mg rectal diclofenac suppository
Number of subjects: 80
Study: 20490573

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg (G2) or placebo (G1 and G3) administered 2 hours prior to surgery and in the PACU
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (G1 and G2)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg (G3)
Number of subjects: 82
Study: 17992347

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 371
Study: 16239358

Group type: EXPERIMENTAL
Intervention: Pradefovir 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pradefovir 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pradefovir 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food effect at 30 mg
Number of subjects: 0
Study: 11194526

Group type: EXPERIMENTAL
Intervention: 3 g of American ginseng (AG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6 g of American ginseng (AG)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 9 g of American ginseng (AG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (0 g of AG)
Number of subjects: 10
Study: 9278463

Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D supplementation (500 mg of calcium plus 700 IU of vitamin D3 per day)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study: 8299295

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 3104960

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3050678

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate
Number of subjects: 47

Group type: COMPARATOR
Intervention: 1% epinephrine
Number of subjects: 47
Study: 31035953

Group type: EXPERIMENTAL
Intervention: Syphilis infection testing
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: History of coerced sexual intercourse
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Sub-district of residence
Number of subjects: 277
Study: 28637449

Group type: EXPERIMENTAL
Intervention: Interpersonal Counseling (IPC) provided by community health workers, 3-4 sessions over 2 months
Number of subjects: 86

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (E-TAU), facilitated referral to specialized mental health care
Number of subjects: 86
Study: 26005188

Group type: EXPERIMENTAL
Intervention: TT with FES applied to GM and TA muscles (TTFES-GM+TA group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TT with FES applied to TA muscle (TTFES-TA group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: TT only (control group)
Number of subjects: 36
Study: 23052650

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation with antibiotics (n=17)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation with antibiotics (n=18)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (antibiotics only; n=25)
Number of subjects: 61
Study: 22077144

Group type: EXPERIMENTAL
Intervention: Apixaban (2.5 mg orally twice daily for 30 days)
Number of subjects: 4495

Group type: COMPARATOR
Intervention: Enoxaparin (40 mg subcutaneously once daily for 6 to 14 days)
Number of subjects: 4495

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4495

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 4495
Study: 19386306

Group type: EXPERIMENTAL
Intervention: Sphincter of Oddi manometry with solid-state catheter (SSC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sphincter of Oddi manometry with water-perfusion triple-lumen catheter (TLC)
Number of subjects: 30
Study: 16770291

Group type: EXPERIMENTAL
Intervention: Home visits for 1 year
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 171
Study: 14705158

Group type: EXPERIMENTAL
Intervention: Exposure to forbidden food (chocolate) for 24 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no special intervention)
Number of subjects: 60
Study: 11696690

Group type: EXPERIMENTAL
Intervention: GIK solution
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 9386027

Group type: EXPERIMENTAL
Intervention: Ultrasound screening during pregnancy
Number of subjects: 3265

Group type: EXPERIMENTAL
Intervention: Ultrasound exposure during pregnancy
Number of subjects: 3265
Study: 7957147

Group type: EXPERIMENTAL
Intervention: Brisk walking programme (n = 48)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 72
Study: 2821784

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (2 mg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (other doses)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31240312

Group type: EXPERIMENTAL
Intervention: 240 g banana + 150 mL control drink
Number of subjects: 12

Group type: COMPARATOR
Intervention: 250 mL control drink (Fresubin 2 kcal fiber, neutral flavor)
Number of subjects: 12
Study: 29231539

Group type: EXPERIMENTAL
Intervention: GAO's neck acupuncture combined with swallowing rehabilitation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Basic pharmaceutical treatment and swallowing rehabilitation (Control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GAO's neck acupuncture (Observation group)
Number of subjects: 100
Study: 26697847

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg to 10 mg over 6 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 23647738

Group type: EXPERIMENTAL
Intervention: Vx-001 + Montanide ISA51 VG (2 mg, subcutaneously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + Montanide ISA51 VG (subcutaneously)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vx-001 + Montanide ISA51 VG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + Montanide ISA51 VG
Number of subjects: 0
Study: 21200319

Group type: EXPERIMENTAL
Intervention: C-MB-P lock solution (0.24 M sodium citrate, 0.15% methylene blue, 0.15% methylparaben, 0.015% propylparaben)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: C-MB-P lock solution
Number of subjects: 407

Group type: COMPARATOR
Intervention: Heparin (5000 units of unfractionated heparin)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 407
Study: 18617304

Group type: EXPERIMENTAL
Intervention: On-line high-flux hemofiltration (HF)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ultrapure low-flux hemodialysis (HD)
Number of subjects: 64
Study: 16691049

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 36
Study: 14515658

Group type: EXPERIMENTAL
Intervention: sevoflurane-nitrous oxide
Number of subjects: 40

Group type: COMPARATOR
Intervention: thiopental-fentanyl
Number of subjects: 40
Study: 11021731

Group type: EXPERIMENTAL
Intervention: 0.25 mg butorphanol tartrate (n = 31)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 0.5 mg butorphanol tartrate (n = 29)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 1.0 mg butorphanol tartrate (n = 30)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 2.0 mg butorphanol tartrate (n = 30)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo (n = 31)
Number of subjects: 151
Study: 9076408

Group type: EXPERIMENTAL
Intervention: Intensive group advice session on F&V intake
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 5-a-day health message with defined discrete portions
Number of subjects: 42
Study: 8439021

Group type: EXPERIMENTAL
Intervention: IsoHigh group (increased isoflurane concentration to 2.6% for 10 min)
Number of subjects: 22

Group type: COMPARATOR
Intervention: IsoLow group (continued isoflurane concentration at 1.3%)
Number of subjects: 22
Study: 3518329

Group type: EXPERIMENTAL
Intervention: Phosphatidylserine (BS-PS) 3 X 100 mg for six weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 30200906

Group type: EXPERIMENTAL
Intervention: Exposure to bright white light therapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Exposure to dim white light (comparison group)
Number of subjects: 128
Study: 26827289

Group type: EXPERIMENTAL
Intervention: GSK1278863 (10, 25, 50, or 100 mg)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: GSK1278863 (10 or 25 mg)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: GSK1278863
Number of subjects: 107
Study: 25218397

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Wait list (control group)
Number of subjects: 130
Study: 22294238

Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 72

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study: 21171482

Group type: EXPERIMENTAL
Intervention: 24% sucrose solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 0
Study: 17081815

Group type: EXPERIMENTAL
Intervention: GLP-2 (1.6 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GLP-2 (3.2 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 60
Study: 16306072

Group type: EXPERIMENTAL
Intervention: Integrated Management of Childhood Illness (IMCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study: 11943529

Group type: EXPERIMENTAL
Intervention: Clo‐eye G (30 microg peribulbar clonidine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CG (oral saline and peribulbar saline)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (including CG)
Number of subjects: 60
Study: 9585928

Group type: EXPERIMENTAL
Intervention: Combined arthroscopic and radiation synovectomy
Number of subjects: 141

Group type: COMPARATOR
Intervention: Radiation synovectomy
Number of subjects: 141

Group type: COMPARATOR
Intervention: Arthroscopic synovectomy
Number of subjects: 141
Study: 8133101

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.15 mg/kg iv every 6 h for 2 days
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.15 mg/kg iv every 6 h for 4 days
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Dexamethasone (both regimens)
Number of subjects: 118
Study: 2697955

Group type: EXPERIMENTAL
Intervention: Nadolol (mean dose 87 mg/day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Propranolol (dose 144 mg/day)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nadolol (doses less than 200 mg/day)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nadolol (doses of 240 and 280 mg/day)
Number of subjects: 2
Study: 241365

Group type: EXPERIMENTAL
Intervention: Kö 1366 (0.0375 mg/kg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Practolol (0.3 mg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31330464

Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Relaxation training control (REL)
Number of subjects: 150
Study: 28558367

Group type: EXPERIMENTAL
Intervention: Sinusitis Hevert SL
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 27005660

Group type: EXPERIMENTAL
Intervention: Carbohydrate mouth rinse (CHO)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13
Study: 24961537

Group type: EXPERIMENTAL
Intervention: Fresh fruit and komatsuna (B. rapa) juice mixture
Number of subjects: 16

Group type: COMPARATOR
Intervention: Commercial vegetable juice
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both juices
Number of subjects: 16
Study: 21668531

Group type: EXPERIMENTAL
Intervention: Behavioural intervention using a self-monitoring and reward system.
Number of subjects: 43

Group type: COMPARATOR
Intervention: General advice on increasing dietary fibre intake (Control).
Number of subjects: 43
Study: 20441243

Group type: EXPERIMENTAL
Intervention: Atorvastatin (30 mg/day for at least 8 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (no atorvastatin therapy)
Number of subjects: 54
Study: 17285097

Group type: EXPERIMENTAL
Intervention: Citalopram (20-40 mg daily)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Amitriptyline (50-100 mg daily)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 291
Study: 16830653

Group type: EXPERIMENTAL
Intervention: BCG vaccine (105 live bacilli/per dose) with 12 months M.D.T.‐MBR
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mw vaccine (1 x 108 killed bacilli as first dose and 0.5 x 108/dose in subsequent doses) with 12 months M.D.T.‐MBR
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline as placebo with 12 months M.D.T.‐MBR
Number of subjects: 60
Study: 11869849

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 3634

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 3634
Study: 10356651

Group type: EXPERIMENTAL
Intervention: Buspirone 15 mg BID
Number of subjects: 289

Group type: COMPARATOR
Intervention: Buspirone 10 mg TID
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Buspirone 15 mg BID and TID
Number of subjects: 289
Study: 7605020

Group type: EXPERIMENTAL
Intervention: Low-dose isoflurane (0.5 MAC)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low-dose desflurane (0.5 MAC)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1.5 MAC isoflurane
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1.5 MAC desflurane
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High-dose propofol (200 micrograms.kg‐1.min‐1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low-dose propofol (0.5 MAC)
Number of subjects: 42
Study: 1899823

Group type: EXPERIMENTAL
Intervention: High-nitrogen, isotonic, enteral feeding solution (Osmolite HN, pH = 6.4) (n = 7)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 0.45 percent NaCl (pH = 5) (n = 6)
Number of subjects: 13
Study: 6337699

Group type: EXPERIMENTAL
Intervention: Dukes' B tumors
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Longest diameter of the primary tumor
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Tumor volume analysis
Number of subjects: 906
Study: 30634590

Group type: EXPERIMENTAL
Intervention: Daily nutritional supplementation with vitamin D₃ (5000 IU) and phenylbutyrate (PBA, 2 × 500 mg)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 30044123

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (rtCGM)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 316